A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men

Autor: Wagensveld, I.M., Osses, D.F., Groenendijk, P.M., Zijta, F.M., Busstra, M.B., Rociu, E., Barentsz, J.O., Sedelaar, J.P.M., Arbeel, B., Roeleveld, T., Geenen, R., Koeter, I., Meer, S.A. van der, Cappendijk, V., Somford, R., Klaver, S., Lely, H. Van der, Wolters, T., Hellings, W., Leter, M.R., Poel, H.G. van der, Heijmink, S., Debruyne, F., Immerzeel, J., Leijte, J., Roermund, J. van, Miclea, R., Planken, E., Vis, Andre N., Jong, I. de, Tijsterman, J., Wolterbeek, D., Claessen, A., Vrijhof, E., Nederend, J., Leenders, G. van, Bangma, Chris H., Krestin, G.P., Remmers, S., Schoots, I.G., Group, M.-M.W.

Publikováno v: European Urology, 82(3), 318-326. ELSEVIER SCIENCE BV
European Urology, 82(3), 318-326. Elsevier
European Urology, 82, 3, pp. 318-326
MR-PROPER Study Group 2022, ' A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging–directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men ', European Urology, vol. 82, no. 3, pp. 318-326 . https://doi.org/10.1016/j.eururo.2022.03.003
European Urology, 82, 318-326

Contains fulltext : 283332.pdf (Publisher’s version ) (Open Access) BACKGROUND: European Association of Urology guidelines recommend a risk-adjusted biopsy strategy for early detection of prostate cancer in biopsy-naive men. It remains unclear whic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78cd194599c1f8aba6029ed2dae59782
https://pubmed.ncbi.nlm.nih.gov/35341658

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

What is an acceptable false negative rate in the detection of prostate cancer?

Autor: Verbeek, J. F., Roobol, Monique J., Bangma, C. H., Kirkels, W. J., Rietbergen, J. B.W., van der Cruijsen, I. W., Raaijmakers, R., de Vries, S. H., Roemeling, S., Gosselaar, C., Wolters, T., van den Bergh, R. C.N., van Leeuwen, P. J., Bul, M., Zhu, Y., van Vugt, H. A., Yurdakul, G., Boeken-Kruger, A., Wijburg, C., Forouzanfor, M., de Boer, M., Vis, A. N., Venderbos, L. D.F., Schröder, Fritz H., Postma, R., van der Kwast, T. H., Hoedemaeker, R., van Leenders, A. G.J.L.H., Blijenberg, B. G., van Schaik, R. H.N., de Koning, H. J., Heijnsdijk, E., van der Maas, P. J., Beemsterboer, P., Otto, S. J., Essink-Bot, M., Korfage, I., Alberts, A. R., Bokhorst, L. P., Drost, F. H., Osses, D. F., Salman, J., Boer, R., Wildhagen, M., Draisma, G., Merkelbach, W., Hoekstra, W., van den Berg, E., Smit, A., the ERSPC Rotterdam study group

Background: In prostate cancer (PCa) screening men and their physicians aim to rule out the presence of potentially life threatening PCa. To date, prostate specific antigen (PSA) testing and systematic prostate biopsy (Bx)-in case of an elevated PSA-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10691::9ec2c13494600c86e158d9c3efc946ac
https://dspace.library.uu.nl/handle/1874/364722